Clinical Trial Update: Cumulative Skin Irritation Potential of a New 25 mg Nicotine Patch [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the cumulative skin irritation potential of a new 25 mg nicotine patch for smoking cessation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nicotine Dependence
• Tobacco Use Disorder

Drugs mentioned

• Nicotine transdermal patch (nicotine patch)

Snippet

Sponsor: McNeil AB | Conditions: Smoking Cessation | Phase 1 | Status: COMPLETED